The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.

DiaGenic patent allowed in Canada

Thursday, 11 April 2013
The Norwegian diagnostic company, DiaGenic announced that it has received notice of allowance for its Canadian family 2 patent application.

The allowed claims cover the use of a set of gene sequences in blood essential for the diagnosis of, among other diseases, Alzheimer’s disease and stages thereof. The patent when granted will be valid until 2023, the company said in a press release.
Scancomark.com Team

We welcome your contribution. Did you find anything wrong with this article? Do you want to contribute to our news network? Do have a news tip or assist us with a correction